Articles
Life Code shares poster from the 25th World Congress of Dermatology Singapore 2023 with Follicle Thought. Artificial Intelligence Small Molecule Enhanced Hair Growth Follicle Thought is pleased to share an exclusive look at Life Code’s poster from the current World Congress of Dermatology event. Just over a year ago, I shared an introduction to Life…
Read More
On June 28, 2023, Amplifica Holdings Group announced the initiation of a clinical trial for one of its lead candidate molecules from the study of hairy moles. Amplifica’s AMP-303 has officially entered a clinical trial. According to a news release on the company’s website and PR Newswire, the first patient was dosed in a multicenter,…
Read More
Things are really heating up in the hair loss treatment industry on the first day of Summer 2023. Let’s take a look at all pertinent information and happenings in the AGA clinical trial world below. Cosmo Pharma Lists Phase 3 Trial On ClinicalTrials.gov A trial which was once highly anticipated, then questioned if it would…
Read More
Follicle Thought is pleased to announce a new company developing a treatment for androgenetic alopecia with an innovative technology. Unlike most other biotechs tackling the challenging field of hair regeneration, StimuSIL is a biomedical device company. Their team has created a completely new way to deliver photobiomodulation and incorporated it into a proprietary, patented hair…
Read More
A company working in protein degradation has entered the field of hair loss therapeutics in Spring 2023 with a new anti-hair loss drug. AH-001 AnHorn Medicines As I’ve stated before, we are in a new era for hair loss medication. Whereas in years past we would see a new therapy or company emerge once per…
Read More
An Indian drug-discovery startup with a focus on dermatology has unveiled its new website. Inovaugmet Research, which was mentioned in a recent article on Follicle Thought, is aiming to bring new therapies to unmet dermatological needs. Inovaugmet utilizes a dermatology-specific drug discovery platform called iNeu-3D screen to find new molecules. From the company’s website, iNeu-3D…
Read More
After a more thorough evaluation of FOL-005’s data from a phase 2 clinical trial, new management at Follicum believes that its drug candidate has a place in the treatment landscape for androgenic alopecia and they want to explain why. FOL-005 Phase 2 Results Revisited In February 2022, Follicum AB was acquired by Coegin Pharma, a…
Read More
On May 11, 2023, Kintor Pharmaceutical of China announced results from their US phase 2 trial testing KX-826 aka pyrilutamide in males with androgenetic alopecia. Successful Phase 2 Trial For US KX-826 Trial As is the trend for Kintor Pharmaceutical’s AGA programs, today’s announcement included positive results in a human trial. This milestone will help…
Read More
A new brief update has been shared about the official launch of the anticipated cosmeceutical CosmeRNA from the siRNAgen & Bioneer companies. CosmeRNA is a topical siRNA serum which inhibits the production of the androgen receptor protein using small interfering RNAs. It has been clinically tested in Korea, and Europe through the Dermatest agency and…
Read More
As we head into Q2 2023, the hair growth treatment industry continues to develop and make progress in various ways. Kintor Begins Phase 2 Trial For GT20029 Drug This news appeared one day following the publishing of this article. Kintor Pharmaceutical of China has dosed the first patient in a trial which will comprise 180…
Read More